Influence of Early Postoperative Basal Insulin Treatment and Post-Transplant Diabetes Mellitus Risk on Health-Related Quality of Life in Kidney Transplant Recipients-An Analysis of Data From a Randomized Controlled Trial.
HRQOL
PTDM
clinical study
insulin
kidney transplantation
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
03
2023
accepted:
17
07
2023
medline:
22
8
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
Health-related quality of life (HRQOL) improves after kidney transplantation (KT) but declines over time. Studies on the effect of early postoperative basal insulin therapy on HRQOL after KT, especially KTRs at high risk of developing post-transplant diabetes mellitus (PTDM) are missing. Data from a randomized controlled trial on 148 non-diabetic KTRs were analyzed. HRQOL using the KDQOL-SF™ was compared in KTRs who either received early postoperative basal insulin therapy or standard-of-care and in KTRs at risk of developing PTDM. Determinants of HRQOL outcomes were investigated using multivariable linear regression analysis. In total, 148 patients completed the KDQOL-SF at baseline. Standard-of-care or early basal insulin therapy after KT did not influence HRQOL. Overall, KT improved the mental (MCS) and physical component summary (PCS) scores at 6-month after KT, which remained stable during further follow-up visits. However, patients at high-risk for PTDM had significantly greater impairment in the PCS score (baseline, 24 months) without differences in MCS scores. In the multivariable regression analysis, allograft function and hemoglobin levels were associated with decreased MCS and PCS scores, respectively. A limitation of the study is the fact that only around 50% of the ITP-NODAT study patients participated in the HRQOL evaluation. Still, our data clearly show that early basal insulin therapy does not affect HRQOL after KT but is negatively influenced by classical clinical factors and PTDM-risk at 24 months after KT. The latter might be influenced by older age.
Identifiants
pubmed: 37600749
doi: 10.3389/ti.2023.11370
pii: 11370
pmc: PMC10432682
doi:
Substances chimiques
Insulins
0
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11370Informations de copyright
Copyright © 2023 Odler, Huemer, Schwaiger, Borenich, Kurnikowski, Krall, Hafner-Giessauf, Eleftheriadis, Bachmann, Faura, José Pérez-Sáez, Pascual, Budde, Rosenkranz, Hecking and Eller.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Transpl Int. 2021 Jan;34(1):27-48
pubmed: 33135259
Qual Life Res. 1994 Oct;3(5):329-38
pubmed: 7841967
N Engl J Med. 2021 Aug 19;385(8):729-743
pubmed: 34407344
Hemodial Int. 2017 Oct;21(4):524-533
pubmed: 27990732
Am J Kidney Dis. 2020 Jun;75(6):868-878
pubmed: 31879215
Kidney Int. 2005 Jun;67(6):2415-21
pubmed: 15882287
Prim Care Companion J Clin Psychiatry. 2004;6(Suppl 1):12-6
pubmed: 16001092
J Pain Symptom Manage. 2019 Mar;57(3):566-575.e3
pubmed: 30552961
J Am Soc Nephrol. 2021 Aug;32(8):2083-2098
pubmed: 34330770
Clin J Am Soc Nephrol. 2009 Apr;4(4):853-9
pubmed: 19339426
Qual Life Res. 2020 Aug;29(8):2063-2072
pubmed: 32215841
Kidney Int Rep. 2020 Oct 24;6(1):138-145
pubmed: 33426393
Kidney Int. 2006 Feb;69(3):588-95
pubmed: 16395250
Transpl Int. 2001;14(1):16-23
pubmed: 11263551
Ther Adv Chronic Dis. 2018 Jul 04;9(11):209-226
pubmed: 30364521
Transplantation. 2007 Apr 27;83(8):1027-34
pubmed: 17452891
Am J Transplant. 2011 Oct;11(10):2093-109
pubmed: 21883901
Semin Nephrol. 2015 Jul;35(4):323-34
pubmed: 26355251
Transpl Int. 2016 May;29(5):568-78
pubmed: 26875590
Saudi J Kidney Dis Transpl. 2020 Jan-Feb;31(1):100-108
pubmed: 32129202
Clin J Am Soc Nephrol. 2010 Sep;5(9):1669-75
pubmed: 20558559
J Strength Cond Res. 2021 Nov 1;35(11):3243-3250
pubmed: 31714457
Clin Transplant. 2002 Dec;16(6):455-60
pubmed: 12437627
Transpl Int. 2020 Apr;33(4):423-436
pubmed: 31919903
Clin Kidney J. 2021 Jul 10;15(1):5-13
pubmed: 35265335
Clin Chim Acta. 2019 Sep;496:35-44
pubmed: 31229566
Nat Rev Endocrinol. 2019 Mar;15(3):172-188
pubmed: 30622369
Diabetes Metab Syndr. 2013 Jul-Sep;7(3):154-60
pubmed: 23953181
Kidney Dial. 2022 Mar;2(1):106-122
pubmed: 35350649
PLoS Med. 2012;9(9):e1001307
pubmed: 22984353
Int J Obes (Lond). 2009 Jun;33(6):635-44
pubmed: 19381155
Am J Kidney Dis. 2019 Jan;73(1):51-61
pubmed: 30037726
Lancet. 2017 Mar 25;389(10075):1238-1252
pubmed: 27887750
Diabetes Care. 2022 Jan 1;45(Suppl 1):S8-S16
pubmed: 34964872
Clin J Am Soc Nephrol. 2021 Nov;16(11):1686-1694
pubmed: 34750161
J Am Soc Nephrol. 2017 Aug;28(8):2498-2510
pubmed: 28270413
Nephrol Dial Transplant. 2021 Dec 2;36(12):2327-2339
pubmed: 34338799
Scand J Med Sci Sports. 2021 Feb;31(2):473-479
pubmed: 33038051
Endocr Rev. 2016 Feb;37(1):37-61
pubmed: 26650437
Transplantation. 2012 Aug 27;94(4):377-82
pubmed: 22820698
Transplantation. 2016 Mar;100(3):640-7
pubmed: 26569063
Clin J Am Soc Nephrol. 2020 Apr 7;15(4):577-584
pubmed: 32086281
Biogerontology. 2016 Jun;17(3):467-83
pubmed: 26667010
Maturitas. 2017 Feb;96:10-15
pubmed: 28041587
Nutr Metab Cardiovasc Dis. 2019 Jul;29(7):736-743
pubmed: 31153746
Am J Transplant. 2003 Feb;3(2):178-85
pubmed: 12603213
Curr Vasc Pharmacol. 2020;18(3):273-281
pubmed: 31258090
J Pain Symptom Manage. 2012 Aug;44(2):229-38
pubmed: 22578312
Transplantation. 2013 Mar 15;95(5):740-9
pubmed: 23354297
JCI Insight. 2016 Jun 2;1(8):
pubmed: 27336062